ROOPAIND.BO Roopa Industries BSE up 23.47% intraday on 23 Mar 2026: watch resistance at INR 57.99

ROOPAIND.BO stock jumped 23.47% intraday on 23 Mar 2026, trading at INR 52.76 on the BSE after a sharp volume surge to 10,509.00 shares. The move pushed the price well above the 50-day average of INR 45.57 and cleared the 200-day average of INR 51.78, signalling renewed buyer interest in Roopa Industries Limited (BSE: ROOPAIND.BO). As an AI-powered market analysis platform, Meyka AI flags this as a top-gainer intraday setup, but traders should weigh valuation and leverage before adding exposure.

ROOPAIND.BO stock intraday price action and volume

Roopa Industries (ROOPAIND.BO) opened at INR 55.00 and hit a day high of INR 57.99 with a low of INR 52.61, closing near INR 52.76 in the intraday session. The stock recorded 10,509.00 shares versus an average volume of 1,118.00, a relative volume of 12.26, which confirms the strength behind the 23.47% move.

Valuation snapshot and fundamentals for ROOPAIND.BO stock

Roopa Industries trades at P/E 20.84 with EPS of INR 2.46 and a market cap of INR 403,265,210.00. Price-to-book stands at 2.21 and debt-to-equity at 1.98, indicating above-average leverage compared with healthcare peers. The company’s EV/EBITDA is 11.38, and the current ratio is 1.25, showing modest short-term liquidity.

Technical levels, momentum and trading cues for ROOPAIND.BO stock

Key support sits at the intraday low INR 52.61 and the 200-day average INR 51.78; resistance is the day high INR 57.99 and the yearly high INR 71.99. Momentum indicators show RSI 42.99 and MACD histogram -0.03, suggesting the rally has room but is not overbought. Traders may treat a break above INR 58.00 as follow-through, while failure below INR 51.78 would signal profit-taking.

Meyka AI rates ROOPAIND.BO with a score out of 100

Meyka AI rates ROOPAIND.BO with a score out of 100: 66.49 / 100 — Grade B — Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Note: these grades are informational only and not financial advice.

ROOPAIND.BO stock forecast and price targets

Meyka AI’s forecast model projects a yearly price of INR 45.32, implying a -14.11% change from the current INR 52.76 (model-based projection, not a guarantee). For intraday traders we outline scenario targets: bull-case target INR 60.00 (up 13.72%), base-case support INR 52.00 (down -1.44%), and model yearly target INR 45.32 (down -14.11%). These levels combine technical triggers and Meyka’s statistical model.

Sector context, risks and catalysts for ROOPAIND.BO stock

Roopa Industries operates in Healthcare (Medical – Pharmaceuticals) where sector average P/E is 37.31, making Roopa’s P/E of 20.84 relatively cheaper on earnings. Primary risks include high leverage (debt-to-equity 1.98) and thin free cash flow metrics. Catalysts that could sustain gains include contract wins, margin expansion, or lower net debt to EBITDA.

Final Thoughts

ROOPAIND.BO stock is the intraday top gainer on 23 Mar 2026, up 23.47% to INR 52.76 on the BSE with high relative volume (10,509.00 v. avg 1,118.00). Valuation metrics show a moderate P/E of 20.84 and a PB of 2.21, below healthcare peers on P/E but burdened by leverage (D/E 1.98). Meyka AI’s model projects a yearly price of INR 45.32, implying -14.11% versus today’s price; however short-term momentum opens a bull target of INR 60.00 (up 13.72%) if buying continues. Traders should watch the clear resistance at INR 57.99 and the 200-day average at INR 51.78 for trade management. Remember, Meyka AI’s grade (66.49/100, B, HOLD) and forecasts are model-based and not guarantees. For live quotes and filings, check the company site and monitor intraday volume when trading ROOPAIND.BO stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.